← Back to Clinical Trials
Recruiting NCT06831045

NCT06831045 Bikini vs Longitudinal Incision in Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06831045
Status Recruiting
Phase
Sponsor University of Miami
Condition THA
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2025-03-01
Primary Completion 2028-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Bikini IncisionLongitudinal Incision

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2025-03-01 with a primary completion date of 2028-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study team is conducting this study to see if there is a difference between the wound healing and participant satisfaction rates between two incision types used during a THA done via the DAA technique.

Eligibility Criteria

Inclusion Criteria: * Patients with body mass index greater than or equal to 30 * Patients undergoing primary unilateral DAA THA * Patients undergoing primary THA Exclusion Criteria: * Patients with body mass index less than 30 * Patients with a history of prior open surgery on the affected hip * Patients unable/unwilling to undergo spinal anesthesia under monitored anesthesia care (MAC) * Patients with allergies or absolute contraindication to standardized drugs administered within the University of Miami protocol for total hip replacement * The following groups will not be included: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.

Contact & Investigator

Central Contact

Victor H Hernandez, MD

✉ vhh1@miami.edu

📞 305-689-5195

Principal Investigator

Victor H Hernandez, MD

PRINCIPAL INVESTIGATOR

University of Miami

Frequently Asked Questions

Who can join the NCT06831045 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying THA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06831045 currently recruiting?

Yes, NCT06831045 is actively recruiting participants. Contact the research team at vhh1@miami.edu for enrollment information.

Where is the NCT06831045 trial being conducted?

This trial is being conducted at Miami, United States.

Who is sponsoring the NCT06831045 clinical trial?

NCT06831045 is sponsored by University of Miami. The principal investigator is Victor H Hernandez, MD at University of Miami. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology